載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.7599
−US$0.014 · -1.81%
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
前收盤價
US$0.7599
−US$0.014 · -1.81%
盤中時間採用ET。市場資料可能有所延遲。
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
日內區間
目前US$0.7599
52週區間
目前US$0.7599
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
50
合理估值
情緒
57
多空交錯
風險
69
高風險
動能
24
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
日內區間
目前US$0.7599
52週區間
目前US$0.7599
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年1月28日 | 1:4 | — | — |
股票分割 | 2025年7月7日 | 1:3 | — | — |
股票分割 | 2025年1月28日 | 1:16 | — | — |
股票分割 | 2024年1月25日 | 1:30 | — | — |
股票分割 | 2023年2月1日 | 1:35 | — | — |
已生效 2026年1月28日
1:4
已生效 2025年7月7日
1:3
已生效 2025年1月28日
1:16
已生效 2024年1月25日
1:30
已生效 2023年2月1日
1:35
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
